ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Chronic Renal Insufficiency
Kidney Diseases
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Insufficiency
Renal Cell Carcinoma
Kidney Cancer

Kidney Disease trials near Toronto, ON, CAN:

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that caus...

Enrolling
Autosomal Dominant Polycystic Kidney Disease
Drug: ABBV-CLS-628
Drug: Placebo

Phase 2

Calico Life Sciences
Calico Life Sciences

Toronto, Ontario, Canada and 91 other locations

people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD)....

Active, not recruiting
Kidney Disease
Drug: Placebo matching GSK4771261
Drug: GSK4771261

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Toronto, Ontario, Canada and 22 other locations

baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney...

Enrolling
Chronic Kidney Disease and Hypertension
Drug: Baxdrostat/dapagliflozin
Drug: Baxdrostat/Placebo

Phase 2

AstraZeneca
AstraZeneca

Etobicoke, Ontario, Canada and 70 other locations

Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors ...

Enrolling
Kidney Failure, Chronic
Diabetic Nephropathies
Drug: Placebo
Drug: Sotagliflozin

Phase 3

Alessandro Doria

Toronto, Ontario, Canada and 18 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: VX-147
Drug: Placebo

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Toronto, Canada and 330 other locations

with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Part...

Enrolling
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

Phase 3

Lilly
Lilly

Brampton, Canada and 560 other locations

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compare...

Begins enrollment this month
Chronic Kidney Disease
Drug: Placebo
Drug: Elecoglipron

Phase 3

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 425 other locations

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific t ...

Active, not recruiting
Chronic Kidney Disease
Drug: Vicadrostat
Drug: Empagliflozin

Phase 2

Boehringer Ingelheim
Boehringer Ingelheim

Toronto, Ontario, Canada and 159 other locations

This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medici...

Enrolling
Chronic Kidney Disease
Drug: Placebo
Drug: Empagliflozin

Phase 3

Boehringer Ingelheim
Boehringer Ingelheim

Toronto, Ontario, Canada and 103 other locations

We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or wi...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Placebo
Drug: Tirzepatide

Phase 2

Lilly
Lilly

Toronto, Canada and 26 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems